We are live on ! Find out more
EIGR

Eiger BioPharmaceuticals, Inc.
EIGR

Delisted

EIGR was delisted on the 10th of April, 2024.

Back to rankings

43 hedge funds and large institutions have $4.17M invested in Eiger BioPharmaceuticals, Inc. in 2023 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 7 increasing their positions, 15 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

16% less funds holding

Funds holding: 51 → 43 (-8)

32% less capital invested

Capital invested by funds: $6.08M → $4.17M (-$1.92M)

53% less repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 15

62% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 13

Holders
43
Holders Change
-8
Holders Change %
-15.69%
% of All Funds
0.63%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
7
Reduced
15
Closed
13
Calls
$1K
Puts
–
Net Calls
+$1K
Net Calls Change
+$1K

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$101K
2
HF
HRT Financial
New York
+$8.54K
3
TSS
Two Sigma Securities
New York
+$6.28K
4
Jane Street
Jane Street
New York
+$4.33K
5
Prudential Financial
Prudential Financial
New Jersey
+$3.52K

Top Sellers

Rank Fund Capital Flow
1
SAM
Simplify Asset Management
Nevada
-$824K
2
Ameriprise
Ameriprise
Minnesota
-$319K
3
6CM
683 Capital Management
New York
-$161K
4
UOC
UBS O'Connor
Illinois
-$120K
5
GCP
GSA Capital Partners
United Kingdom
-$109K
Name Holding Trade Value Shares
Change 		Change in
Stake
Ameriprise
1
Ameriprise
Minnesota
$1.68M -$319K -36,231 -13%
PBM
2
Propel Bio Management
California
$986K +$1.29M +146,381 New
6CM
3
683 Capital Management
New York
$471K -$161K -18,333 -21%
Vanguard Group
4
Vanguard Group
Pennsylvania
$409K -$42.1K -4,785 -7%
BlackRock
5
BlackRock
New York
$131K -$88.6K -10,080 -34%
Geode Capital Management
6
Geode Capital Management
Massachusetts
$85.3K – – –
Renaissance Technologies
7
Renaissance Technologies
New York
$77K +$101K +11,474 New
RC
8
RBF Capital
California
$76K -$15.4K -1,751 -13%
Acadian Asset Management
9
Acadian Asset Management
Massachusetts
$38K -$18.7K -2,131 -27%
State Street
10
State Street
Massachusetts
$33K – – –
Northern Trust
11
Northern Trust
Illinois
$25.2K – – –
Millennium Management
12
Millennium Management
New York
$18.2K -$55.1K -6,271 -70%
SFA
13
Sequoia Financial Advisors
Ohio
$14.1K – – –
TSS
14
Two Sigma Securities
New York
$12.8K +$6.28K +714 +60%
Verition Fund Management
15
Verition Fund Management
Connecticut
$12.2K -$2.44K -277 -13%
Bank of America
16
Bank of America
North Carolina
$10.8K -$642 -73 -4%
TAM
17
Tocqueville Asset Management
New York
$8.38K -$4.04K -459 -27%
DI
18
DFPG Investments
Utah
$7.98K – – –
Charles Schwab
19
Charles Schwab
California
$7.51K – – –
TC
20
TownSquare Capital
Utah
$7.28K – – –
Jane Street
21
Jane Street
New York
$6.62K +$4.33K +493 +100%
Morgan Stanley
22
Morgan Stanley
New York
$6.2K -$545 -62 -6%
HF
23
HRT Financial
New York
$6K +$8.54K +971 New
Susquehanna International Group
24
Susquehanna International Group
Pennsylvania
$5.73K +$1.12K +127 +18%
Bank of New York Mellon
25
Bank of New York Mellon
New York
$4.63K – – –
1
2 3

EIGR Hedge Fund Activity: Q4 2023 in Review

43 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Eiger BioPharmaceuticals, Inc. (EIGR) for Q4 2023, worth a combined $4.17M — down 32% from $6.08M a quarter earlier.

Sellers outnumbered buyers: 13 funds closed out of EIGR and 5 opened new positions — a net loss of 8 holders — while 15 trimmed existing stakes and 7 added.

The largest buyer was Renaissance Technologies, opening a new position worth an estimated $101K. The largest seller was Simplify Asset Management, exiting entirely with an estimated $824K sold.

  • 43 institutional investors held Eiger BioPharmaceuticals, Inc. (EIGR) as of Q4 2023, down from 51 in Q3 2023.
  • Funds reported $4.17M of Eiger BioPharmaceuticals, Inc. stock for Q4 2023, down 32% quarter-over-quarter.
  • 5 funds opened new Eiger BioPharmaceuticals, Inc. positions in Q4 2023 and 13 closed out, a net change of -8 holders.
  • The largest Eiger BioPharmaceuticals, Inc. buyer in Q4 2023 was Renaissance Technologies, an estimated $101K added.
  • The largest Eiger BioPharmaceuticals, Inc. seller in Q4 2023 was Simplify Asset Management, an estimated $824K sold.

Based on aggregated 13F filings for Q4 2023.